Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01287195 · ClinicalTrials.gov registry record · Phase 1
Oral OKT3 for the Treatment of Active Ulcerative Colitis
A Phase 1 study of Ulcerative Colitis, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT01287195 is a Phase 1 study of Ulcerative Colitis that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 6 participants, below the 2,057-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01287195, a Phase 1 study of Ulcerative Colitis, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will assess the safety and efficacy of orally delivered short-term OKT3 in participants with active ulcerative colitis.
Conditions Studied
Interventions
- DRUG Omeprazole
- DRUG Oral OKT3
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2011-04-07 |
| Est. Completion | 2013-05-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01287195
The ClinicalTrials.gov registry entry for NCT01287195 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,057-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (100% lower). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ulcerative Colitis appearing as the primary indexed condition, and to 2 interventions - of which Omeprazole is the first listed.
NCT01287195 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01287195 about?
NCT01287195 is a clinical study titled "Oral OKT3 for the Treatment of Active Ulcerative Colitis". This study will assess the safety and efficacy of orally delivered short-term OKT3 in participants with active ulcerative colitis.
What is the current status of trial NCT01287195?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2011-04-07. Estimated completion is 2013-05-02.
What conditions does trial NCT01287195 study?
This clinical trial studies the following conditions: Ulcerative Colitis.
What interventions are being tested in trial NCT01287195?
The interventions under investigation include: Omeprazole (DRUG), Oral OKT3 (DRUG).
Who is sponsoring clinical trial NCT01287195?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01287195 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ulcerative Colitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Use of Butyrate Therapy in Pediatric Ulcerative Colitis
RECRUITING · Phase 1
-
R-3750 in Patients With Mild to Moderate Ulcerative Colitis
RECRUITING · Phase 1
-
Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy
RECRUITING · Phase 1
-
CP101 for the Treatment of Ulcerative Colitis
ACTIVE NOT RECRUITING · Phase 1
-
Angiographic Delivery of AD-MSC for Ulcerative Colitis
ACTIVE NOT RECRUITING · Phase 1
-
Safety, Tolerability, and Pharmacokinetics of Oral NX-13 in Active Ulcerative Colitis
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.